Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenetic study of gemcitabine and CDA polymorphism in resected pancreatic adenocarcinoma
2010-022987-11Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Fédération Francophone de Cancérologie Digestive. Started Dec 2010; status: completed.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2010-022987-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022987-11.